A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.
Cannabis Use Disorder Heart Attack Study: 7 Crucial Reality Checks
A new Cannabis Use Disorder Heart Attack Study suggests increased cardiovascular risk in hospitalized MASH cirrhosis patients—but what was actually measured may surprise you. This physician-led analysis separates diagnosis codes from pharmacology and headlines from nuance. Before we panic—or dismiss—we should read carefully, think clearly, and protect hearts with precision rather than fear.
The Canadian Association of Gastroenterology Requires Guidance when Recommending Medical Cannabis
Canadian Association of Gastroenterology position statement- use of cannabis in gastroenterological and hepatic disorders In Summary The Canadian Association of Gastroenterology has stated that guidance is required on the issues of relevance...